Posted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's lymphoma (follicular lymphoma).
Once again, the recommendation has an important caveat; the uncertainty in its cost-effectiveness needs to be reduced (which is code for a price reduction).
